Business Directory, Press Releases, Jobs, Products, Services, Articles
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | News on Your Site

Press Releases


Press Release

Share      Blog

Receive press releases from ALPCO: By Email PDF Version RSS Feeds:

ALPCO’s New STELLUX® Chemi Active GLP-1 ELISA Offers High Sensitivity with Low Sample Volume

The new STELLUX® Chemi Active GLP-1 ELISA from ALPCO features superior sensitivity and requires only 10 µL of sample.

ALPCO’s New STELLUX® Chemi Active GLP-1 ELISA Offers High Sensitivity with Low Sample Volume
Salem, NH, September 13, 2016 --( ALPCO has launched its new STELLUX® Chemi Active GLP-1 ELISA specific for the determination of the (7-36 amide) GLP-1 fragment, which is the prime biologically active form of GLP-1 in humans and mice. The newest addition to the STELLUX® Chemiluminescence line of assays features superior sensitivity of < 1 pM, making it ideal for quantifying fasted levels of active GLP-1. Additionally, the assay only requires 10 µL of human or rodent samples and does not cross-react with any pro-glucagon derived fragments.

“Current GLP-1 ELISAs on the market require large sample volumes or special instrumentation to achieve the desired sensitivity and detect fasting levels of circulating GLP-1,” explains ALPCO’s President, Sean Conley. “We developed the STELLUX® Chemi Active GLP-1 ELISA to eliminate the variability of questionable results, while also increasing precision and accuracy for users.”

The STELLUX® Chemi Active GLP-1 ELISA is For Research Use Only. The assay does not require any sample extraction and has a range of 0.66 - 1355 pM. Visit to learn more about the new STELLUX® Chemi Active GLP-1 ELISA.

American Laboratory Products Company (ALPCO) was founded in 1991 as an importer and distributor of immunoassay-based products for the North American life science markets. The company has since grown into a premier channel representing over 60 collaborating partners from around the globe. In 2008, ALPCO expanded its capabilities with the launch of an organically developed product line focused in the area of diabetes and obesity research while also remaining true to its roots by continuing to provide “Immunoassays Beyond the Ordinary.”
Contact Information
Nirja Patel

Click here to view the list of recent Press Releases from ALPCO
Promote Your Business